Low-THC Cannabis Extract Shows Promise for Rett Syndrome Symptoms in Girls

An open-label trial of 11 girls with Rett syndrome found a full-spectrum cannabis extract (0.08% THC) improved communication, alertness, anxiety, and quality of life over 12 weeks.

Keating, B A et al.·Journal of paediatrics and child health·2025·LowOpen-Label Clinical Trial
RTHC-06807Open Label Clinical TrialLow2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Open-Label Clinical Trial
Evidence
Low
Sample
N=11

What This Study Found

NTI164 improved global clinical impression (p = 0.028), communication skills (p = 0.003), socialization/eye contact (p = 0.0004), attentiveness (p = 0.001), anxiety (p = 0.004), and quality of life (p = 0.0002) in 11 girls with genetically confirmed Rett syndrome over 12 weeks.

Key Numbers

11 participants; improvements in communication (p = 0.003), eye contact/socialization (p = 0.0004), attentiveness (p = 0.001), anxiety (p = 0.004), quality of life (p = 0.0002), caregiver burden (p = 0.006).

How They Did This

Phase I/II open-label study of 11 female participants aged 5-16 years with pathogenic MECP2 variants. NTI164 administered twice daily for 12 weeks with multiple validated outcome measures.

Why This Research Matters

Rett syndrome is a severe neurodevelopmental disorder with very limited treatment options. While this is a small open-label study, the consistency of improvements across multiple validated outcome measures is noteworthy for a condition with few effective interventions.

The Bigger Picture

Several groups are exploring cannabinoid therapies for rare neurological conditions. Rett syndrome, caused by mutations in a single gene (MECP2), offers a relatively well-defined population for studying potential benefits.

What This Study Doesn't Tell Us

Very small sample (n = 11) with no control group or blinding. Open-label design means placebo and caregiver expectation effects cannot be ruled out. 12-week duration may not capture long-term effects or tolerance.

Questions This Raises

  • ?Would a placebo-controlled trial confirm these improvements?
  • ?Which components of the full-spectrum extract are most responsible for the observed effects?

Trust & Context

Key Stat:
Socialization/eye contact improved with p = 0.0004
Evidence Grade:
Small open-label study without a control group, though it used genetically confirmed participants and multiple validated outcome measures.
Study Age:
2025 publication
Original Title:
Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study.
Published In:
Journal of paediatrics and child health (2025)
Database ID:
RTHC-06807

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

Can cannabis help with Rett syndrome?

In this small open-label trial, a low-THC cannabis extract improved communication, eye contact, attention, anxiety, and quality of life in 11 girls with Rett syndrome. However, without a control group, placebo effects cannot be ruled out.

What type of cannabis product was used for Rett syndrome?

The study used NTI164, a full-spectrum medicinal cannabis extract containing only 0.08% THC, administered twice daily. It contains multiple cannabinoids beyond just CBD and THC.

Read More on RethinkTHC

Cite This Study

RTHC-06807·https://rethinkthc.com/research/RTHC-06807

APA

Keating, B A; Ogru, Y; Duthy, T G; Douglas, L; Lichkus, K; Isikgel, E; Fahey, M C; Ellaway, C. (2025). Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study.. Journal of paediatrics and child health. https://doi.org/10.1111/jpc.70122

MLA

Keating, B A, et al. "Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open-Label Study.." Journal of paediatrics and child health, 2025. https://doi.org/10.1111/jpc.70122

RethinkTHC

RethinkTHC Research Database. "Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NT..." RTHC-06807. Retrieved from https://rethinkthc.com/research/keating-2025-fullspectrum-medicinal-cannabis-plant

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.